Skip to main content
. 2021 Dec 18;94(4):1617–1626. doi: 10.1002/jmv.27512

Figure 5.

Figure 5

Meta‐regression and sensitivity analyses for the efficacy and safety of medications in patients with severe COVID‐19 infection. (A) All‐cause mortality. (B) The ratio of treatment‐emergent adverse events. CD, crossover design; COVID‐19, coronavirus disease 2019; DS, duration of study; IS, industry sponsorship; MS, multicenter study; RRB, risk of reported bias; SS, sample size